[{"orgOrder":0,"company":"APIRx","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tetrahydrocannabivarin","moa":"CBR","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"APIRx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"APIRx \/ Incannex","highestDevelopmentStatusID":"4","companyTruncated":"APIRx \/ Incannex"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabivarin","moa":"CBR","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"InMed Pharmaceuticals \/ Radicle Science","highestDevelopmentStatusID":"12","companyTruncated":"InMed Pharmaceuticals \/ Radicle Science"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabivarin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"InMed Pharmaceuticals \/ BayMedica","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ BayMedica"}]

Find Clinical Drug Pipeline Developments & Deals for Tetrahydrocannabivarin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : delta 9-dominant tetrahydrocannabivarin, d9-THCV is the naturally-occurring variant found in the Cannabis plant, to create unique health and wellness products.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 09, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Sponsor : Baymedica

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Tetrahydrocannabivarin, also known as THCV, or d9-THCV, is a naturally occurring compound of the Cannabis sativa plant, and is an analog of the better known major cannabinoid, tetrahydrocannabinol (“THC”).

                          Brand Name : d9-THCV

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 05, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : Radicle Science

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : A focus of the combined APIRx and Incannex group will be the ongoing development of APIRx's CheWell, CanQuit and CanQuit-O cannabinoid combination MCGs to treat cannabis addiction, nicotine addiction and opioid addiction.

                          Brand Name : CheWell

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 24, 2022

                          Lead Product(s) : Tetrahydrocannabivarin

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Incannex Healthcare

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank